What We're Reading: Pharma Execs Prep for Senate; UnitedHeathcare Loses Case; Wyo. Work Requirements
February 25th 2019The grilling that pharmaceutical company executives are expected to face Tuesday before the Senate Finance Committee is reminiscent of previous hearings with businesses that proved to be turning points; UnitedHealthcare lost its case to prevent a former executive from working at the new healthcare venture formed by Amazon, Berkshire Hathaway, and JPMorgan Chase; a bill to establish work requirements for thousands of Medicaid recipients in Wyoming passed its first reading in the state’s House.
What We're Reading: Importing Insulin; Teen Depression and Anxiety; Gene Editing Guidelines
February 21st 2019A bill would allow the importation of insulin from Canada and other countries; a survey highlighted the prevalence of anxiety and depression among teens; and the World Health Organization has established a committee to set guidelines for gene editing.
What We're Reading: Young Blood Injections; Gilead Accused of Kickbacks; Minor Consent for PrEP
February 20th 2019The FDA is warning against services offering to inject older adults with younger people's blood plasma; Gilead is being accused of providing kickbacks to providers to boost sales of its drugs; and a bill in Maryland would allow minors to consent to preventive treatment for HIV.
What We're Reading: Kaiser Permanente's Tuition Offer; Menopause and the Brain; Air Force and HIV
February 19th 2019Kaiser Permanente will waive annual tuition for the first 5 classes of its new medical school, following a similar move by the New York University School of Medicine; menopause is typically thought of in terms of the end of fertility, but more attention is being paid to the effects of the lack of estrogen on the brain; a federal judge has ordered the US Air Force to temporarily stop discharging service members who are HIV-positive.
What We're Reading: Syphilis Rates Rising; House Democrats and ACA Suit; WHO to Look at Gene Editing
February 15th 2019Drug use is fueling record-high syphilis rates around the nation, a CDC report said; the Fifth Circuit Court of Appeals is allowing House Democrats to defend the Affordable Care Act (ACA) in a lawsuit that challenges the law’s constitutionality; the World Health Organization (WHO) is convening an expert meeting in March to develop global standards for the governance and oversight of human gene editing.
What We're Reading: Lowering Age of Medicare; Depression Drug Endorsed; Limiting Chemicals in Water
February 14th 2019Democrats have introduced a bill that would allow anyone over age 50 to buy into Medicare; an FDA advisory panel has endorsed a ketamine-like depression drug; and the EPA is set to limit the amount of manmade chemicals allowed in drinking water.
What We're Reading: Dietary Supplement Action; AI in Healthcare; Border Crossings for Medicine
February 12th 2019An FDA announcement that it would step up oversight of the $50-billion-a-year dietary supplements industry was met with mixed reaction; a group of researchers in the United States and China are testing artificial intelligence (AI) to automatically diagnose common childhood conditions after processing data; close to 1 million people in California alone cross the border to Mexico annually for healthcare, including to buy prescription drugs.
What We're Reading: EPA and Drinking Water; Teens Seek Vaccines; Companies Cut Praluent Price
February 11th 2019The Environmental Protection Agency (EPA) is expected to make a decision soon regarding stricter regulations of polyfluoroalkyl compounds, or PFAS, which are chemicals in coatings meant to protect consumer goods from stains, water, and corrosion that have been found in drinking water; teenagers are turning to Reddit and other sites to figure out how to get vaccinated if their parents subscribe to antivaccine beliefs; Regeneron and Sanofi announced they are cutting the price of its proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab (Praluent).
What We're Reading: J&J to Show Drug Prices; SCOTUS Blocks Abortion Law; Democrats' Medicare Bill
February 8th 2019Johnson & Johnson will become the first drug maker to begin showing the list price of its prescription drugs in television ads; in a 5-4 decision, the Supreme Court blocked a Louisiana law that required doctors performing abortions to have admitting privileges at nearby hospitals; Democrats unveiled a bill to allow Medicare to negotiate drug prices.
What We're Reading: Obesity and Cancer; Second Patient Treated Under Right-to-Try; Brain Aging
February 6th 2019Cancers related to obesity are on the rise, especially among millennials; a right-to-try advocate is receiving treatment for his amyotrophic lateral sclerosis under the new law; and women's brains age more slowly than men's.
What We're Reading: Trump May Include HIV Plan in Speech; Judge Tosses ACA Suit; CF Treatment Gaps
February 4th 2019While President Trump's State of the Union address is not finalized, he may plan to unveil a promise to end HIV transmission in America by 2030; a federal judge dismissed a lawsuit brought by Maryland that claimed the Trump administration is failing to enforce the Affordable Care Act; new cystic fibrosis (CF) treatments targeting the genetic mutations that cause the disease help about 90% of patients, meaning that 10% are still waiting for a cutting-edge therapy.
What We're Reading: Right-to-Try Law Frustrations; Microbiome Links Explored; Measles Consequences
January 29th 2019The man for whom the right-to-try law is named has been unable to get treatment; neuroscientists who were once skeptics are now being persuaded by new studies that have turned up fascinating links between the microbiome and the brain; public health officials are worried it could take months to contain the measles outbreak due to a lower-than-normal vaccination rate in Clark County, Washington, the epicenter of the crisis.
What We're Reading: Drug Pricing Proposals; Idaho Medicaid Expansion; Business and Biosimilars
January 25th 2019Presumed 2020 presidential candidates are trying to stake a claim to one of healthcare’s main concerns—surging prescription drug prices; enrollment in Idaho's health insurance exchange is expected to drop by 20% due to Medicaid expansion; employer groups can help overcome barriers, such as patient fears and misinformation, and create confidence about using biosimilars.